Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

(2020) Aiping Wu et al.   Cell Host & Microbe

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

(2020) Shuai Xia et al.   Cellular & Molecular Immunology

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

(2020) Jared S. Morse et al.   CHEMBIOCHEM

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

(2020) Haibo Zhang et al.   INTENSIVE CARE MEDICINE

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

(2020) David S. Hui et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

(2020) Xin Liu et al.   Journal of Genetics and Genomics

A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option

(2020) Tian‐Tian Yao et al.   JOURNAL OF MEDICAL VIROLOGY

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

(2020) Abdo A. Elfiky   LIFE SCIENCES

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

(2020) Syed Faraz Ahmed et al.   Viruses-Basel

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

(2020) Canrong Wu et al.   Acta Pharmaceutica Sinica B

Potential Therapeutic Targets and Promising Drugs for Combating SARS‐CoV‐2

(2020) Hong Zhou et al.   BRITISH JOURNAL OF PHARMACOLOGY

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking

(2020) Ran Yu et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

(2020) Yung-Fang Tu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

(2020) Nisha Muralidharan et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19: a fast evolving pandemic

(2020) Jimmy Whitworth   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives

(2020) Jiumeng Sun et al.   TRENDS IN MOLECULAR MEDICINE

Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs

(2020) Paolo Calligari et al.   Viruses-Basel

Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19

(2020) Santosh Kumar et al.   Viruses-Basel

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

(2020) Catrin Sohrabi et al.   International Journal of Surgery

Use of antiviral drugs to reduce COVID-19 transmission

(2020) Oriol Mitjà et al.   Lancet Global Health

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

(2020) Cynthia Liu et al.   ACS Central Science

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach

(2020) Syed Ovais Aftab et al.   Journal of Translational Medicine

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

(2020) Abdo A. Elfiky   LIFE SCIENCES

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

(2020) Muhammad Adnan Shereen et al.   Journal of Advanced Research

Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents

(2019) Elmira Ekincia et al.   Recent Patents on Anti-Cancer Drug Discovery

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

(2019) Egor Tchesnokov et al.   Viruses-Basel

Ribavirin and Interferon Therapy for Critically Ill Patients with the Middle East Respiratory Syndrome: A multicenter observational study

(2019) Yaseen Arabi et al.   CLINICAL INFECTIOUS DISEASES

Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126

(2019) Kathryn Fischer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application

(2019) Lee   Marine Drugs

Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes

(2018) Min-Han Lin et al.   ANTIVIRAL RESEARCH

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

(2018) Jonna B. Westover et al.   ANTIVIRAL RESEARCH

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase 2b Trial

(2018) Sulggi A. Lee et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Danoprevir: First Global Approval

(2018) Anthony Markham et al.   DRUGS

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

(2017) Timothy P. Sheahan et al.   Science Translational Medicine

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

(2016) Mizuki Yamamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin

(2016) Jean K. Millet et al.   ANTIVIRAL RESEARCH

Using an Old Drug to Target a New Drug Site: Application of Disulfiram to Target the Zn-Site in HCV NS5A Protein

(2016) Yu-Ming Lee et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential

(2016) Sabrina Lusvarghi et al.   Viruses-Basel

Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430

(2014) Travis K. Warren et al.   NATURE

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine β-Hydroxylase

(2010) Jason P Schroeder et al.   NEUROPSYCHOPHARMACOLOGY

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

(2009) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae

(2009) B. R. O'Keefe et al.   JOURNAL OF VIROLOGY